Keep in mind the revenue this Q we have already banked a...

Keep in mind the revenue this Q we have already banked a $2.4mill payment from Access Bio right at the start. Then if trajectory of ordinary sales matches last Q's we'd be looking at $4mill + for the 2nd Q bringing us in line with FY21 full year revenue of +$6mill. All with another 6 months left in FY22 to improve on this result.

Furthermore, I wont be surprised if ordinary sales outpace Q1 revenue as we obviously had to contend with supply shortages given the limited amount of RAT we kept on shore when demand surged in July/Aug. Given the recent commentary from JK it sounds like the "substantial" order they placed for RAT a few months back was expected to get us through to Christmas so this should boost sales maybe even allowing use to better last years full year result by the first half FY22?